Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Is telmisartan effective in treating non-alcoholic steatohepatitis?

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

2 Apr 2009

Low dose medication best for treating high blood pressure

A newly published study found patients actually have more control of their high blood pressure (hypertension) when treated with less medication.

20 Mar 2009

Factors associated with proteinuria identified

Characteristics associated with proteinuria - a predictor of decline in child kidney function - have been identified, according to a study appearing in the March 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN).

20 Mar 2009

New target for heart failure therapy identified

A novel signaling pathway plays a significant role in the production of aldosterone, a hormone that promotes heart failure after a myocardial infarction, according to a study conducted by Thomas Jefferson University researchers.

16 Mar 2009

Seniors with 1 type of heart failure may receive little or no benefit from drugs

People over 80 years of age suffering from a certain type of heart failure do not appear to benefit from most commonly prescribed heart medications, according to a study conducted at the Cedars-Sinai Heart Institute and published in the March 15 issue of The American Journal of Cardiology.

12 Mar 2009

Trial looks at telmisartan in treating non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

3 Mar 2009

Blood pressure drug losartan may benefit brain tumor patients

A widely used blood pressure medication may be the key to preventing brain function loss common after radiation treatment, according to a newly published study by researchers at Wake Forest University Baptist Medical Center.

20 Feb 2009

Does gene show link between migraine and stroke or heart attacks?

New research looks at whether a gene variant may affect the link between migraine and stroke or heart attacks.

16 Feb 2009

Candesartan cilexetil reduces proteinuria in kidney disease patients

Taking a much higher than recommended dose of the hypertension drug candesartan cilexetil effectively lowered the amount of protein excreted in the urine of patients with kidney disease, according to a study appearing in the April 2009 issue of the Journal of the American Society Nephrology ( JASN ).

11 Feb 2009

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

While the treatment of heart failure has improved over the past two decades, a new study reported in the European Journal of Heart Failure finds that "the use of evidence-based treatments appears to be imbalanced according to the gender of the patient".

23 Jan 2009

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

21 Jan 2009

Seasonal variation in blood pressure

A French study reported in the 12th January issue of Archives of Internal Medicine has found a strong correlation between blood pressure and outdoor temperature in a large sample of the elderly.

19 Jan 2009

Candesartan shown to be safe new therapy for genetic heart disease

A new clinical trial suggests that long-term use of candesartan, a drug currently used to treat hypertension, may significantly reduce the symptoms of genetic heart disease.

1 Jan 2009

Researchers create new family of fluorescent probes called hydrocyanines to detect reactive oxygen species in vivo

Researchers have created a new family of fluorescent probes called hydrocyanines that can be used to detect and measure the presence of reactive oxygen species.

15 Dec 2008

Generics as good as brand-name drugs when treating heart diseases

Contrary to the perception of some patients and physicians, there is no evidence that brand-name drugs are clinically superior to their generic counterparts, according to an article in the December 3 issue of JAMA, which examined studies comparing the effectiveness of generic vs. brand-name drugs for treating cardiovascular diseases.

3 Dec 2008

Diuretic reduces risk for type of heart failure that affects women more often than

New research by The University of Texas School of Public Health shows that a medication for high blood pressure called a diuretic or water pill is particularly effective at reducing the risk for a type of heart failure that affects women more often than men.

11 Nov 2008

FDA approves Ranexa for the treatment of chronic angina

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina.

7 Nov 2008

Experts available to comment on risk of sudden cardiac death in 30 days following a heart attack

A new study in the November 5th 2008 issue of JAMA finds that during the first month after a heart attack, patients may have an increased risk for sudden cardiac death.

5 Nov 2008

New York City blacks more likely than other races to have high blood pressure, report finds

New York City blacks have the highest rate of high blood pressure of any racial or ethnic group in the city, according to a report released on Wednesday by the New York City Department of Health and Mental Hygiene, the Staten Island Advance reports.

29 Sep 2008

The BEAUTIFUL study: Ivabradine and the reduction of cardiovascular events

The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.

31 Aug 2008